Mountain View, California, United States
As a Board Director at iCAD Medical and Avenda Health, Mr. Michael Klein leverages his extensive experience and expertise in artificial intelligence and medical technology to guide and support the strategic vision and growth of these innovative companies. iCAD Medical is a clinical AI company focused on the detection of breast cancer and other proliferative diseases, as well as the use of novel electronic brachytherapy for the treatment of various cancers. Avenda Health is a medical software company that develops focal ablation technology for prostate cancer treatment. Mr. Klein has over 20 years of experience as a medical technology executive and entrepreneur, with a proven track record of leading and growing companies that develop breakthrough solutions for challenging medical problems. He holds an MBA from New York Institute of Technology and completed an advanced executive education program at Harvard. He is passionate about driving innovation and improving patient outcomes in the fields of AI, software, and medical technology. He has been recognized as a two-time finalist for the Entrepreneur of the Year award in California, and has multiple patents and publications in his name.
Medical Software for Urological Disease as well as focal ablation technology for prostate cancer treatment.
AI technology for the detection breast cancer and other proliferative disease. Additionally the use of guided precision radiation therapy for the treatment of skin, brain and breast cancer.
Artificial Intelligence Image Interpretation Technologies & Intra-Operative Radiation Therapy (IORT)
Executives looking to raise funds, accelerate commercial growth, enhance value creation and create compelling product brands and offerings. "One on one coaching" for CEO's looking to better manage both launch and ramp, improve interactions with their Board's or commencing the fundraising process. Regularly scheduled meetings provide the coaching desired to navigate a path towards the company's "inflection point." Consulting and Training & Development Programs for Management Teams are also available. See www.inflectionpointconsult.com
An innovative and disruptive technology that deploys high frequency ultrasound technology to treat prostate cancer with exceedingly precise contours and a dramatically reduced side effect profile designed to protect surrounding structures. Technology linked novel imaging technology with focal treatment to deliver precise therapeutic treatments with minimal side effects. Dramatically ramped Int'l Business (400%) and launched US commercial ramp for a novel therapeutic ultrasound systems-used to treat dozens of soft tissue cancers throughout the body. Achieved nearly 15,000 successful treatments outside the US before launching within the US. Secured 4 rounds of financing (both equity and debt) in excess of $35M. Total funds raised in prior CEO assignments was well over $100M in private equity and venture funding.